SG11201708294YA - Pyridopyrimidinones and their use as nmda receptor modulators - Google Patents
Pyridopyrimidinones and their use as nmda receptor modulatorsInfo
- Publication number
- SG11201708294YA SG11201708294YA SG11201708294YA SG11201708294YA SG11201708294YA SG 11201708294Y A SG11201708294Y A SG 11201708294YA SG 11201708294Y A SG11201708294Y A SG 11201708294YA SG 11201708294Y A SG11201708294Y A SG 11201708294YA SG 11201708294Y A SG11201708294Y A SG 11201708294YA
- Authority
- SG
- Singapore
- Prior art keywords
- pyridopyrimidinones
- nmda receptor
- receptor modulators
- nmda
- modulators
- Prior art date
Links
- IAAQUOVTPAMQCR-UHFFFAOYSA-N 1h-pyrido[3,2-d]pyrimidin-2-one Chemical class C1=CC=C2NC(=O)N=CC2=N1 IAAQUOVTPAMQCR-UHFFFAOYSA-N 0.000 title 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 title 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
- C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Addiction (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2015076617 | 2015-04-15 | ||
| PCT/EP2016/057962 WO2016166078A1 (en) | 2015-04-15 | 2016-04-12 | Pyridopyrimidinones and their use as nmda receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201708294YA true SG11201708294YA (en) | 2017-11-29 |
Family
ID=55809078
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201708294YA SG11201708294YA (en) | 2015-04-15 | 2016-04-12 | Pyridopyrimidinones and their use as nmda receptor modulators |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US10280165B2 (enExample) |
| EP (1) | EP3283487B1 (enExample) |
| JP (2) | JP6847851B2 (enExample) |
| KR (1) | KR20170137137A (enExample) |
| CN (1) | CN107531696B (enExample) |
| AU (1) | AU2016248886B2 (enExample) |
| BR (1) | BR112017021083A2 (enExample) |
| CA (1) | CA2982217A1 (enExample) |
| CL (1) | CL2017002498A1 (enExample) |
| CO (1) | CO2017009989A2 (enExample) |
| CR (1) | CR20170462A (enExample) |
| IL (1) | IL254921B (enExample) |
| MX (1) | MX373162B (enExample) |
| PE (1) | PE20180316A1 (enExample) |
| PH (1) | PH12017501876A1 (enExample) |
| RU (1) | RU2717665C2 (enExample) |
| SG (1) | SG11201708294YA (enExample) |
| UA (1) | UA120647C2 (enExample) |
| WO (1) | WO2016166078A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3055315B1 (en) | 2013-10-11 | 2018-07-25 | F. Hoffmann-La Roche AG | Thiazolopyrimidinones as modulators of nmda receptor activity |
| AU2016248886B2 (en) | 2015-04-15 | 2020-09-10 | F. Hoffmann-La Roche Ag | Pyridopyrimidinones and their use as NMDA receptor modulators |
| SI3386591T1 (sl) | 2015-12-09 | 2020-11-30 | Cadent Therapeutics, Inc. | Heteroaromatski NMDA receptorski modulatorji in njihove uporabe |
| ES2975336T3 (es) | 2016-12-22 | 2024-07-04 | Novartis Ag | Moduladores del receptor NMDA y usos de los mismos |
| JOP20210020A1 (ar) | 2018-08-03 | 2021-01-25 | Cadent Therapeutics Inc | معدلات عطرية غير متجانسة لمستقبل nmda واستخداماتها |
| PE20230609A1 (es) | 2020-05-04 | 2023-04-13 | Amgen Inc | Compuestos heterociclicos como agonistas del receptor de activacion expresado en las celulas mieloides 2 y metodos de uso |
| TW202208355A (zh) | 2020-05-04 | 2022-03-01 | 美商安進公司 | 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6951875B2 (en) * | 2001-10-29 | 2005-10-04 | Hoffmann-La Roche Inc. | Conjugated aromatic compounds with a pyridine substituent |
| US7148226B2 (en) | 2003-02-21 | 2006-12-12 | Agouron Pharmaceuticals, Inc. | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same |
| AU2004249730A1 (en) * | 2003-06-20 | 2004-12-29 | Novartis Vaccines And Diagnostics, Inc. | Pyridino(1,2-A)pyrimidin-4-one compounds as anticancer agents |
| NL2000397C2 (nl) | 2006-01-05 | 2007-10-30 | Pfizer Prod Inc | Bicyclische heteroarylverbindingen als PDE10 inhibitoren. |
| MX2009008338A (es) * | 2007-02-05 | 2009-08-12 | Xenon Pharmaceuticals Inc | Compuestos de piridopirimidinona de utilidad en el tratamiento de enfermedades o condiciones patologicas mediadas por los canales de sodio. |
| JP6130061B2 (ja) * | 2013-06-19 | 2017-05-17 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | インドリン−２−オン又はピロロ−ピリジン／ピリミジン−２−オン誘導体 |
| EP3055315B1 (en) * | 2013-10-11 | 2018-07-25 | F. Hoffmann-La Roche AG | Thiazolopyrimidinones as modulators of nmda receptor activity |
| AU2016248886B2 (en) | 2015-04-15 | 2020-09-10 | F. Hoffmann-La Roche Ag | Pyridopyrimidinones and their use as NMDA receptor modulators |
-
2016
- 2016-04-12 AU AU2016248886A patent/AU2016248886B2/en not_active Ceased
- 2016-04-12 MX MX2017013101A patent/MX373162B/es active IP Right Grant
- 2016-04-12 WO PCT/EP2016/057962 patent/WO2016166078A1/en not_active Ceased
- 2016-04-12 CA CA2982217A patent/CA2982217A1/en not_active Abandoned
- 2016-04-12 SG SG11201708294YA patent/SG11201708294YA/en unknown
- 2016-04-12 BR BR112017021083-5A patent/BR112017021083A2/pt not_active IP Right Cessation
- 2016-04-12 KR KR1020177032061A patent/KR20170137137A/ko not_active Ceased
- 2016-04-12 CN CN201680021960.3A patent/CN107531696B/zh active Active
- 2016-04-12 RU RU2017139254A patent/RU2717665C2/ru active
- 2016-04-12 PE PE2017002006A patent/PE20180316A1/es unknown
- 2016-04-12 CR CR20170462A patent/CR20170462A/es unknown
- 2016-04-12 EP EP16718618.8A patent/EP3283487B1/en active Active
- 2016-04-12 UA UAA201711077A patent/UA120647C2/uk unknown
- 2016-04-12 JP JP2017553877A patent/JP6847851B2/ja active Active
-
2017
- 2017-09-29 CO CONC2017/0009989A patent/CO2017009989A2/es unknown
- 2017-10-03 CL CL2017002498A patent/CL2017002498A1/es unknown
- 2017-10-08 IL IL254921A patent/IL254921B/en active IP Right Grant
- 2017-10-13 PH PH12017501876A patent/PH12017501876A1/en unknown
- 2017-10-13 US US15/783,373 patent/US10280165B2/en active Active
-
2020
- 2020-12-03 JP JP2020200946A patent/JP2021046428A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016166078A1 (en) | 2016-10-20 |
| PE20180316A1 (es) | 2018-02-09 |
| US10280165B2 (en) | 2019-05-07 |
| BR112017021083A2 (pt) | 2018-07-03 |
| IL254921A0 (en) | 2017-12-31 |
| CO2017009989A2 (es) | 2018-01-05 |
| CL2017002498A1 (es) | 2018-04-20 |
| AU2016248886B2 (en) | 2020-09-10 |
| KR20170137137A (ko) | 2017-12-12 |
| CN107531696B (zh) | 2021-03-16 |
| AU2016248886A1 (en) | 2017-10-12 |
| MX2017013101A (es) | 2018-01-30 |
| JP6847851B2 (ja) | 2021-03-24 |
| UA120647C2 (uk) | 2020-01-10 |
| RU2017139254A3 (enExample) | 2019-09-30 |
| EP3283487A1 (en) | 2018-02-21 |
| EP3283487B1 (en) | 2019-10-16 |
| CN107531696A (zh) | 2018-01-02 |
| RU2717665C2 (ru) | 2020-03-24 |
| IL254921B (en) | 2021-02-28 |
| HK1245259A1 (zh) | 2018-08-24 |
| CA2982217A1 (en) | 2016-10-20 |
| PH12017501876A1 (en) | 2018-02-26 |
| MX373162B (es) | 2020-04-21 |
| RU2017139254A (ru) | 2019-05-15 |
| JP2018511627A (ja) | 2018-04-26 |
| US20180127414A1 (en) | 2018-05-10 |
| CR20170462A (es) | 2018-02-01 |
| JP2021046428A (ja) | 2021-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201807731B (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| IL286107A (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| ZA201800827B (en) | Substituted 4-azaindoles and their use as glun2b receptor modulators | |
| IL274537A (en) | nuclear receptor modulators | |
| IL240166A0 (en) | spiro-lactam modulators of the NMDA receptor and their uses | |
| IL264514B (en) | Spiro-lactam nmda receptor modulators and their uses | |
| IL240164A0 (en) | spiro-lactam modulators of the NMDA receptor and their uses | |
| IL240163B (en) | spiro-lactam modulators of the NMDA receptor and their uses | |
| IL247847B (en) | ror gamma modulator and their use | |
| IL240162A0 (en) | spiro-lactam modulators of the NMDA receptor and their uses | |
| IL264488A (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| IL240165A0 (en) | spiro-lactam modulators of the NMDA receptor and their uses | |
| IL254921A0 (en) | Pyridopyrimidinones and their uses as nmda receptor modulators | |
| LT3386591T (lt) | Heteroaromatiniai nmda receptoriaus moduliatoriai ir jų panaudojimas | |
| IL249203A0 (en) | Androgen receptor modulators and methods of using them | |
| ZA201606656B (en) | Ror-gamma modulators and uses thereof |